Item 8.01 Other Events.

On January 5, 2023, Graphite Bio, Inc. (the "Company") issued a press release titled "Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.



Exhibit Number                             Description
99.1           Press Release dated January 5, 2022 titled "  Graphite Bio Announces
               Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene
               autogedtemcel (nula-cel) for Sickle Cell Disease.  "
104            Cover Page Interactive Data (embedded within the Inline XBRL
               document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses